E
nteroviruses are a family of single-stranded, positive-sense RNA viruses of Picornaviridae (1) . Although most of the enterovirus-associated diseases are mild and asymptomatic, some members in the family can cause severe diseases and death, especially in the young and immunocompromised. Enteroviruses are the leading cause of aseptic meningitis, which in turn is the most common infection of the central nervous system (2) . Enterovirus 71 (EV71) is an important pathogen, in addition to polioviruses, of the family. It is emerging as the most significant neurotropic enterovirus in some area of the world in outbreaks and epidemics of hand, foot, and mouth disease (HFMD) (3) (4) (5) . This virus circulates in the United States, and 26% of the adults tested in a study had antibody (6) . An epidemic of enterovirus 71 infection in 1998 in Taiwan resulted in over 400 cases of neurologic diseases and an estimated 1.5 million cases of HFMD and herpangina (7) . Outbreaks of EV71-associated diseases have also been reported in the United States, Australia, Sweden, Japan, Bulgaria, Hungary, Hong Kong, Malaysia, Vietnam, and China (8) (9) (10) (11) (12) (13) (14) (15) (16) . It has been associated with a variety of clinical diseases, including HFMD, herpangina, aseptic meningitis, encephalitis, and even fatal pulmonary edema or hemorrhage (17) . Enterovirus can also cause severe chronic diseases, such as dermatomyositis, polymyositis, dilated cardiomyopathy, and diabetes mellitus (2) .
Upon infection, a polyprotein is translated from the single open reading frame in the genome of an enterovirus and is processed into mature proteins by virally encoded 2A and 3C/3CD proteinases (3C pro /3CD pro ) (1) . The 2A proteinase (2A pro ) is an enzyme that cleaves at its own N terminus, at the junction between VP1 and 2A of the polyprotein. Besides its essential role in processing the viral proteins, 2A pro shuts off the host's cap-dependent protein production by cleaving the elongation factors eIF4GI/II for the synthesis of viral proteins (18, 19) . The 2A pro of coxsackievirus B3 and other similar viruses in the enterovirus family cleaves dystrophin, a cytoskeletal protein, and is directly linked to dilated cardiomyopathy (20) . 2A
pro from polioviruses also interferes with the nuclear traffic (21) (22) (23) and hijacks the splicing and transcription machinery (24) . It is of great importance to understand the structural basis of 2A pro function to assist in the design and development of therapeutics for the treatment of associated diseases. However, there is a gap in our knowledge of 2A pro , as its current structure reveals no space for substrate binding. Here we determined the crystal structures of EV71 2A
pro and its complex with the substrate. The structure revealed an open substrate-binding cleft connecting from the S5 site to the active site and then extending to a possible S3= site. Comparative studies with other 2A pro proteins and molecular dynamic (MD) simulation indicated that the open conformation could be closed with a hinge motion in the bII2 and cII ␤ strands. The open cleft provides an accessible template for docking chemical compounds and indicates a useful system for structure-based design and development of therapeutics to treat associated diseases.
MATERIALS AND METHODS
Protein expression and purification. The cDNA encoding EV71 2A pro was synthesized based on EV71 strain E2004104-TW-CDC (GenBank accession no. EF373576). It was amplified by PCR and inserted into the pGEX-4T-1 vector (GE Healthcare) to generate a plasmid containing the coding sequence of N-terminal glutathione S-transferase (GST) fusion 2A pro . A single mutation was made at the active site nucleophile (C110A). The cDNA encoding 2A pro substrate peptide corresponding to the VP1-2A cleavage junction (ITTL*GKFG) was also inserted in the pGEX-4T-1 vector (GE Healthcare) to generate a plasmid containing the coding sequence of N-terminal GST fusion 2A pro substrate. Following verification of its DNA sequence, Escherichia coli strain BL21(DE3) pLysS (Novagen) was transformed with the vectors pGEX-4T-1-2A pro and pGEX-4T-1-2Asub. The bacterial cultures were grown at 37°C to an optical density at 600 nm (OD 600 ) of 0.6, and 0.4 mM isopropyl-␤-D-thiogalactoside (IPTG) was added to induce 2A pro or substrate expression at 20°C for 12 h. Bacteria were subsequently harvested. For the purification of EV71 2A pro , the bacteria were lysed by ultrasonication in lysis buffer (phosphate-buffered saline [PBS], pH 7.4). The lysate was centrifuged at 36,000 ϫ g for 30 min to remove cell debris. The supernatant was loaded onto a glutathione-Sepharose column (GE Healthcare). After washing with PBS (pH 7.4) for several column volumes, the GST tag was removed with thrombin in PBS at 22°C overnight. A Superdex 75 16/60 column (GE Healthcare) was preequilibrated with a buffer containing 50 mM Tris-HCl (pH 8.0), and then the 2A pro was loaded onto the column and the fractions containing 2A pro were collected. The protein was concentrated to 10 mg/ml with a Centricon centrifugal filter unit (molecular weight cutoff [MWCO], 3,000) for crystallization. For the purification of EV71 2A pro substrate, the GST fusion 2A pro substrate was loaded onto a glutathione-Sepharose column (GE Healthcare) and the GST tag was removed by thrombin. The 2A pro substrate was collected and mixed with the purified 2A
pro at a molar ratio of 1:3 for 2 h. The complex was then concentrated to 10 mg/ml with a Centricon centrifugal filter unit (MWCO, 3,000) for crystallization.
For the enzymatic activity assay, the native sequence of EV71 2A pro was inserted in the pET-28a vector (Novagen) to generate a plasmid containing the coding sequence of the protein with a C-terminal 6ϫHis tag. The vector was transformed into Escherichia coli strain BL21(DE3)/pLysS (Novagen) for protein expression with the same protocol as for pGEX-4T-1-2A pro . The cells were harvested and lysed in PBS (pH 7.4), and the supernatant was loaded onto an Ni-nitrilotriacetic acid (NTA) column and eluted with 20 mM sodium phosphate (pH 7.4)-500 mM NaCl-150 mM imidazole. The protein solution was concentrated to 6 mg/ml and stored at Ϫ80°C for enzymatic activity assay.
Enzymatic activity assay. A fluorescent peptide with the sequence Dabcyl-KSRTAITTLGKFGQQSGE-Edans was employed as the substrate for the 2A pro enzymatic and inhibition assays based on the fluorescence resonance energy transfer (FRET) effect. The sequence is derived from the VP1/2A junction of the polypeptide. The fluorescence was monitored at 500 nm with the excitation wavelength set at 340 nm using a fluorescence spectrophotometer (Cary Eclipse). The experiments were carried out in 20 mM Tris-HCl (pH 7.5) and 100 mM NaCl at 30°C. The measurements in the first 5 min were used to calculate the initial rates. The GraphPad Prism 5 program (GraphPad Software, Inc.) was used to calculate the K m and 95% confidence intervals. The K m was expressed as the best-fit value Ϯ standard error of the mean (SEM).
Protein crystallization. Crystallization of EV71 apo-2A pro and complexes with substrate were carried out at 16°C by hanging-drop vapor diffusion. The 2A pro crystals were made with a well solution containing 0.1 M HEPES (pH 7.5), 20% 2-propanol, and 10% polyethylene glycol (PEG) 4000.
Substrate peptides were generated for crystallographic studies of complex structures. The sequence for the recombinant peptide was GSITTLG KFG. The sequences for the 10 synthetic peptides of 11 residues each were SRTAITTLGKF, SRTAITTMGKF, SRTAITTRGKF, SRTAITFLGKF, SRT AITFMGKF, SRTTITTLGKF, SRTFITTLGKF, SRTTITFLGKF, SRTTITT RGKF, and SRTFITTRGKF. The crystals of the 2A pro /substrate complex were obtained under conditions similar to those for apo-2A
pro . X-ray data collection, processing, and structure determination. The crystals were transferred into a solution containing 0.1 M HEPES (pH 7.5), 20% 2-propanol, 10% PEG 4000, and 25% PEG 400 as a cryoprotectant prior to flash cooling to 100 K for data collection. X-ray diffraction data were collected using a Rigaku rotating-anode X-ray generator ( ϭ 1.5418 Å) equipped with a MAR Research 345-mm imaging plate and processed with the Automar package from Marresearch GmbH. Diffraction data were also obtained under synchrotron radiation, but the quality was not significantly improved and the resolution was not extended. (27, 28) , and Refmac5 (29, 30) . To determine the 2A pro /substrate complex structure by molecular replacement, the refined 2A pro structure was used as the initial phasing model. The substrate is located in the 2mF o -DF c electron density map. The complex structure was refined with Refmac5. The statistics for data collection and refinement are given in Table 1 . The presentations were made with the PyMOL Molecular Graphics System, version 1.4 (Schrödinger LLC).
Modeling the interaction between 2A pro and its substrate. The catalytic triads were superposed between the complex structure of EV71 2A pro , with the partial substrate and the crystal structure of a 3C pro from coxsackievirus A16 (CVA16), in complex with its substrate of 11 amino acid residues (P10 to P1) (Protein Data Bank accession code 3SJ9). Poly(Ala) of the P6-P3 moiety from the CVA16 3C pro complex structure was built onto the substrate sequence (P2-P2=) in EV71 2A
pro . After the residues were mutated to those of the native substrate sequence for EV71 2A
pro , an initial model for the P6-P2= substrate was generated by Prime (Schrödinger) in the substrate-binding cleft of the EV71 2A
pro structure. The model complex structure was further optimized using Prime (Schrödinger) MM-GBSA with default settings that freeze 2A pro atoms but allow the substrate atoms to adjust during the energy minimization. Protein structure accession numbers. The coordinates of the crystal structures were deposited into the Protein Data Bank under accession numbers 4FVB and 4FVD.
RESULTS

Kinetic properties of EV71 2A
pro . The overexpressed and purified EV71 2A
pro was employed to investigate the kinetic properties of the enzyme by a method based on fluorescence resonance energy transfer (FRET) (31) . Derived from the VP1/2A junction of the polypeptide (Fig. 1A) , the substrate is a fluorescent peptide with the sequence Dabcyl-KSRTAITTLGKFGQQSGE-Edans. The optimal conditions for the catalytic activity were identified in a twodimensional grid of varying pH and NaCl concentration. As shown in Fig. 1B , the best conditions for the proteolytic activity of EV71 2A pro are 20 mM Tris-HCl (pH 7.5) and 100 mM NaCl at 30°C. A K m of 6.46 Ϯ 0.77 M was derived, and the 95% confidence interval of the K m is between 4.82 and 8.10 M (Fig. 1C) .
Structure of EV71 2A pro . The sequence identity for the 2A pro proteins of EV71 and coxsackievirus A16, two leading causative agents in HFMD, is 97%. That between EV71 and other coxsackieviruses A and B, including echoviruses, is about 75%. Polioviruses have a lower identity of about 60%. In contrast, the sequence identity with 2A pro of human rhinoviruses, another group of picornaviruses encoding the enzyme, is below 40%. The sequences around the active site and zinc-binding residues are highly conserved among 2A pro proteins from different viruses ( Fig. 2A ). An EV71 2A pro mutant in which the active site Cys110 was mutated to Ala was crystallized at pH 7.5, the optimal pH. The crystal structure was determined to 1.90-Å resolution by molecular replacement with 2A pro from human rhinovirus 2 (HRV2) (32) as the initial phasing model ( Table 1 ). The electron density is well defined for residues 7 to 144. The fold of EV71 2A
pro is similar to those of HRV2 2A pro (32) and coxsackievirus B4 (CVB4) (33) , with an N-terminal domain of a four-stranded antiparallel ␤ sheet with a small ␣ helix, which is a modified chymotrypsin fold (32) , and a C-terminal domain of a six-stranded antiparallel ␤ barrel with a tightly bound zinc atom (Fig. 2B ).
There is a cleft across the surface of EV71 2A pro with a constriction at one end where the active-site residues are located in the current structure (Fig. 3A) . This is in contrast to the other struc (Fig. 2) . His21 functions as the general base, while Cys110 is the nucleophile which is replaced by Ala in this structure. The activesite residues can be superposed well between EV71 and HRV2 2A pro (Fig. 2C ).
In the Protein Data Bank, the CVB4 2A pro structure is represented by 17 structures (PDB accession code 1Z8R). The root mean square deviation (RMSD) between C␣ atoms in the 17 structures is between 1.6 to 3.8 Å. Most comparative studies for CVB4 2A pro here were made with the first set of coordinates in 1Z8R. The RMSD between the C␣ atoms of CVB4 and EV71 2A pro is 9.0 Å if the structures are aligned by the LSQ routine in Coot (26) . Better alignment could be obtained with the secondarystructure matching (SSM) routine (34) in Coot, and the corresponding core RMSD is 1.35 Å, which is the RMSD between the aligned C␣ atoms. For comparison, the RMSD between the C␣ atoms of HRV2 and EV71 2A pro is 3.7 Å by LSQ, and the core RMSD is 1.14 Å by SSM. This is indicative that the core structures of CVB4 and EV71 2A pro are similar. The variations in CVB4 2A pro are a reflection of the dynamic nature of the enzyme (33) . Since one member of the catalytic triad, Cys110, was in a region that was not well defined (33) , no further comparison on the active-site residues from CVB4 2A pro was made. The cleft is long enough to accommodate the P5 to P1 residues of the substrate, using the nomenclature used by Schechter and Berger (35) , and is connected to the S= sites across the active site (Fig. 3A) . If the active site is placed on the right, the south rim of the cleft is formed by the C-terminal domain with the active-site residue Cys110 under the rim in the narrow part of the cleft. While the N-terminal domain forms the northeast floor of the cleft along with the active residues of His21 and Asp39, the north rim is formed by the bII2-cII loop from the C-terminal domain ( and 3A). The S1 site is a shallow binding pocket with the oxyanion hole (32) underneath. It appears to be able to accommodate a side chain of moderate size. In the substrate-binding cleft, the S2 site is considerably larger and deeper under the north rim. This is not obvious in the other two 2A pro structures, where the bII2-cII loop moves southward to compress the space (32, 33) (Fig. 3A and C) . Although there is a clear opening in the substrate-binding cleft, it is still significantly narrower than the S1 and S2 sites of 3C pro , the other cysteine protease encoded in the EV71 genome (Fig. 3A and  4A ). This is so because the bII2-cII loop is folded over the S2 site and active residues His21 and Asp39, while the ␤ ribbon at the similar location in 3C pro is not (36) (Fig. 3A and 4A and B) . If the substrate-binding cleft in EV71 2A pro is described as a canyon, then the S1, S2, S1=, and active sites in 3C
pro form a basin. The distance from S1 to S2 across the canyon is about 10 Å (Fig. 3A) , while the distance across the basin in the north-south direction is about 20 Å (Fig. 4A) . This is indicative that the inhibitors targeting the active site of 3C pro might not be suitable for 2A pro . The narrow cleft around the S1 and S2 sites, as well as across the active site, indicates a better chance of fitting noncovalent inhibitors in 2A pro . The S3, S4, and S5 sites are characterized by generally similar features that can be fitted with amino acid side chains along a groove. Another significant feature of the EV71 2A pro substrate binding is the uneven but accessible potholed contour surround- ing the possible S3= site (Fig. 3B) , which is absent in 3C pro (36) (Fig. 4) . This difference is due to the absence of a similar aI-bI loop in 3C pro , which covers the region (Fig. 4B ). An open conformation. Despite the overall similarity in fold, the north rims of the substrate-binding clefts of EV71, HRV2, and CVB4 2A pro reveal striking differences in conformation ( Fig. 3A  and C) . If the C-terminal domains are superposed, the bII2-cII loop of EV71 2A pro in the north rim would have to slide southward to overlap the loops in HRV2 and CVB4 2A
pro . In addition, the tip of the loop would have to bend further downward to those of CVB4 2A
pro , where the substrate-binding cleft is all but inaccessible to substrate (Fig. 3A and C) . The distance between the tips of the bII2-cII loops in EV71 and HRV2 2A pro is about 3 Å. The distance between those in EV71 and CVB4 2A pro is about 7 Å. The movement of the bII2-cII loop originates at a hinge motion of the bII2 and cII ␤ strands, which unfold part of the fully extended ␤ structures in EV71 2A pro to make a kink in HRV2 and CVB4 2A pro (Fig. 3A and C) . The consequence of this closure of the cleft is that the substrate peptides can no longer be fitted into the current HRV2 and CVB4 2A pro structures because of space con- straints (Fig. 3A) . In light of the facts that the bII2-cII loop of HRV2 2A pro is also variable between the two copies of the enzyme in the asymmetric unit of the crystal, the residues in this region have higher temperature factors (with an average of about 65 Å 2 for C␣ atoms) and weaker electron density than other regions of HRV2 2A
pro structure (32) , and CVB4 2A pro is a substrate-free solution structure, it is conceivable that the bII2-cII loop of 2A pro is a region susceptible to conformational change in response to the substrate binding, with the conformations found in the structures of HRV2 and CVB4 2A pro for a substrate-free state and the conformation found in EV71 2A
pro representing an open conformation for binding the substrate, which is supported by the structural characterization of the 2A pro /substrate complex (see below). It is known that crystal packing has induced conformational changes in the structural elements directly involved in the intermolecular interaction in 3C
pro (36) (37) (38) (39) . The molecular contacts between EV71 2A pro in the crystal were investigated. There are two types of intermolecular contacts in the EV71 2A pro crystal (Fig.  5A) . Neither of these contacts was directly associated with the bII2-cII loop. One of the contacts interacted with the N-terminal domain, although it was in the vicinity of the bII2-cII loop in the C-terminal domain (Fig. 5A) . The closest distance between the bII2-cII loop and the neighboring N-terminal domain is 5 Å. The other contact involved the direct protrusion of the neighboring His25 into the substrate-binding cleft, but it interacted at the south rather than the north rim of the cleft (Fig. 5A ). In addition, its dislodgement by the substrate did not alter the opening of the cleft (Fig. 5B) . This indicated that the adoption of a different conformation by the bII2-cII loop was not an artifact of crystal packing. It might be argued that this interaction with the neighboring His25 could represent an initial event in the 2A pro interaction with the substrate, however, in which the binding of a side chain from the substrate into the cleft would alter the dynamics of the structure to favor the open conformation and to make the cleft fully accessible to the substrate.
MD simulation. To evaluate the flexibility of the bII2-cII loop, an 8-nanosecond molecular dynamic (MD) simulation was carried out. EV71 2A pro was placed in a periodic water box containing 150 mM NaCl to generate the MD trajectory. The RMSD for the C␣ atoms, with respect to the first MD frame obtained after solvent equilibration, shows that the system became thermodynamically stable after approximately 3 ns in the MD simulation (Fig.  6A) . The C␣ distance between residues Glu88 and Pro107 was used as a measurement for the opening of the substrate-binding cleft. Glu88 is the residue at the tip of the bII2-cII loop. Pro107 is at the other side of the cleft in EV71 2A
pro . This distance varied dynamically between 8.5 and 16 Å in a periodic manner due to the movement of the bII2-cII loop (Fig. 6B ).
An MD simulation with the same settings was also carried out for the HRV2 2A pro (PDB accession code 2HRV). The result showed that HRV2 2A pro is much more stable than EV71 2A pro (Fig. 6C) , although the movement between C␣ of the equivalent Glu84 and Pro103 could be as large as 12 Å. The C␣ distance between residues Glu88 and Pro107 in the EV71 2A pro crystal structure is 11.1 Å, while the corresponding distance in HRV2 2A pro crystal structure is 8.2 Å (Fig. 6D) . Interaction with the substrate. Eleven substrate peptides were employed for the crystallization of the complex. After many trials, a complex was obtained by cocrystallization with the Cys110Ala mutant and an octopeptide derived from the VP1-2A pro junction of the precursor polypeptide. The structure was determined to 1.66-Å resolution in the same space group of the peptide-free enzyme. The EV71 2A pro structure in the complex closely resembles the apo structure, with an RMSD of 0.24 Å. The average B factor was also similar for the bII2-cII loop at about 25 Å 2 for C␣ atoms. The substrate interaction dislodged but did not completely displace the interaction from the neighboring His25 in the substrate-binding cleft (Fig. 5B ). Probably as a consequence of this His25 interaction, which interferes with the substrate binding, the density was not fully connected (Fig. 7A) , and only 4 residues of the substrate, with a sequence of TL/GK, were modeled in the electron density at the S2-S2= sites (Fig. 7A) . The P2 residue, a Thr, forms hydrogen bonds with residues Arg93 and Gln95 and is placed snugly in a pocket which can accommodate side chains larger than that of Thr. S1 is a shallow binding site, and its specificity toward Leu seems mainly due to space constraint around it. However, the space is open and can accommodate other residues in the upward direction, which probably explains the lack of specificity at S1 (40) . A Gly residue at the P1= site is probably due to the fact that the active site of the enzyme is highly constricted, and only the smallest residues can be accommodated. No interaction could be identified for P2=, probably because the electron density for its side chain is not well defined ( Fig. 7A and B) .
P6-P2= substrate-binding model. Only a partial structure of the substrate was visualized in the complex. To get a better understanding of the 2A pro interaction with the substrate, a model was generated for the full peptide binding at the cleft. Since both 2A pro and 3C
pro are cysteine proteinases, it is conceivable that the structure of the P3-P6 moiety for 2A pro could be referenced from the counterpart in 3C
pro . The complex structures of EV71 2A pro , with the tetrapeptide substrate and the complex structure between coxsackievirus A16 (CVA16) 3C
pro and its P1-P10 substrate (PDB accession code 3SJ9), were superposed on the catalytic triads and the P1-P2 moieties. The poly(Ala) derived from the P6-P3 moiety in 3C
pro was built onto the P2-P2= substrate structure in the 2A pro complex structure, and the initial model was made with the sequence TAITTL/GK, the sequence at the P1/P2 junction of the polyprotein. After energy minimization, the P6-P2= substrate model of EV71 2A pro was generated (Fig. 8A) . It is apparent that there are only small changes in the P1-P2 structure of the substrate in 2A
pro . This suggests that the addition of other residues and the removal of His25 from the crystal packing would induce minimal perturbation to the peptide. The model substrate fit reasonably well into the substrate-binding cleft without any unfavorable geometry and clash between the enzyme and the substrate (Fig. 8A) . The modeling of the substrate peptide onto the substrate-binding cleft in HRV2 2A pro would result in clashes between the peptide and the enzyme, especially around P2 (Fig. 8B) . This is indicative that there would be a conformational change in the substratebinding cleft of 2A pro for the recognition of the substrate.
DISCUSSION
2A
pro plays multiple roles in enterovirus infection. On one hand, it is a vital component in the life cycle of the virus, as it cleaves its own N terminus during virus replication. On the other hand, it is essential for the viral usurpation or interference of host functions, such as the shutdown of cap-dependent translation of host proteins to facilitate the cap-independent translation of viral polyprotein (18, 19) , the cleavage of dystrophin by that of coxsackievirus B3 (20) , and the inhibition of nuclear traffic and splicing and transcription machineries by poliovirus 2A pro (21) (22) (23) (24) . It is important to understand the structural basis of 2A pro function and develop a framework for the design of therapeutics.
There are characteristic differences in the substrate-binding clefts between the two proteinases encoded in the enterovirus genome. This provides the structural basis for designing specific 2A pro and 3C pro inhibitors. The ␤ ribbon in 3C pro is peninsula-like with S2, S3, and S4 sites around it, but it does not fold over the S2 site (36) . This results in a more exposed architecture around the active sites of S1 and S2. This more exposed architecture might be the reason that P2 is highly variable among 3C pro substrates (41) and the reason for more tolerance to chemical groups taking different binding positions at S2 without diminishing the potency of a 3C pro inhibitor (36) . In contrast, the folding of the bII2-cII loop in 2A pro over the S2 site and active-site residues makes the binding cleft more confined.
In this crystal structure, a neighboring His25 binds inside the substrate-binding cleft but not at the bII2-cII loop. It is not unreasonable to suggest that this interaction with a neighboring His25 might be analogous to an initial event in the substrate interaction with the enzyme. As the bII2-cII loop can vary among different conformations, as was demonstrated by MD simulation and the CVB4 2A pro structure, an interaction with the side chain of the substrate peptide in the south rim of the substrate-binding cleft would tip the balance and facilitate the opening of the substrate-binding cleft, which lends support to the notion that the substrate binding induces the conformational change.
The more confined substrate-binding cleft compared to that in 3C pro provides more constraint for fitting chemical compounds and a better chance to develop noncovalent inhibitors targeting EV71 2A
pro . Another distinct feature of the EV71 2A pro structure is the potholed contour surrounding the possible S3= site, which can be targeted for fitting compounds bridged across the active site. As there are no specifically designed 2A pro activity inhibitors to date, the EV71 2A pro structure provides a framework for the rational design and development of therapeutics to successfully target enterovirus-associated diseases. We gratefully acknowledge the crystallographic data collection at beamline BL17U1 at Shanghai Synchrotron Radiation Facility. pro . There are steric clashes around the P2 site, highlighted by an oval. In order to bind the substrate in a fashion similar to that for EV71 2A pro , the conformation of the bII2-cII loop would have to change.
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